Journal of Asthma最新文献

{"title":"Association of short-term exposure to PM_2.5 and its components with hospital admission for asthma in Shanghai: a time-stratified case-crossover study.","authors":"Xuesong Zhou, Jia Qiu, Ning Kang, Jingwei Zhang, Yandan Xu, Jian Zhang, Xiuli Tang, Yinghao Yuchi, Mingjia Xu, Chongjian Wang","doi":"10.1080/02770903.2025.2478503","DOIUrl":"10.1080/02770903.2025.2478503","url":null,"abstract":"<p><strong>Introduction: </strong>Associations between PM_2.5 and the risk of asthma admission have been established in previous researches. However, evidence about the specific impacts of PM_2.5 components on asthma-related hospitalizations across different populations and environments is limited and inconsistent. The purpose of this study was to examine the association between short-term exposure PM_2.5 and its components with asthma hospital admission.</p><p><strong>Method: </strong>A total of 930 people hospitalized for asthma were included in the study in Shanghai between December 2018 and December 2022. Air pollution data were assigned to individuals based on their residential address using the Tracking Air Pollution (TAP) platform. A time-stratified case-crossover design and a conditional logistic regression model were used to estimate the risk of asthma admissions related to exposure to PM_2.5. We also conducted stratified analyzes by age, gender, and season.</p><p><strong>Results: </strong>Each 10 μg/m³ increase in PM_2.5, BC, NO₃^-, NH₄⁺, SO₄^2- and OM at lag-5 day were associated with increased risk of asthma admission, with ORs of 1.04(1.00,1.08), 2.59(0.99,6.76), 1.17(1.02,1.33), 1.33(1.06,1.66), 1.28(1.05,1.55) and 1.16(0.98,1.37), respectively. Stratified analysis showed that PM_2.5 and its components had a more significant impact on the risk of asthma admission for women; individuals aged ≥ 65 years, and during cold seasons at lag-5 day. The results remained stable in the sensitivity analysis.</p><p><strong>Conclusion: </strong>Short-term exposure to PM_2.5 and its components (NO₃^-, NH₄⁺, SO₄^2-) increases hospitalization risk in asthma patients, particularly among women, elder and those admitted during cold seasons. It provides new insight for reducing the asthma burden associated with particulate air pollution.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1341-1350"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal relationships between allergic diseases and significant declines in lung function: a multivariable Mendelian randomization study.","authors":"Jiannan Lin, Xiaoyu Zhao, Shuwen Lu","doi":"10.1080/02770903.2025.2472359","DOIUrl":"10.1080/02770903.2025.2472359","url":null,"abstract":"<p><strong>Background: </strong>Asthma and other allergic diseases are increasing globally each year, with some patients experiencing the co-occurrence of two or more conditions, significantly impacting their quality of life. While these diseases may share certain immune mechanisms, the independent causal relationships between them and lung function remain unclear.</p><p><strong>Objective: </strong>This study aims to investigate the independent and interactive effects of allergic asthma, atopic dermatitis, allergic rhinitis, and allergic conjunctivitis on significant declines in lung function. By elucidating the potential causal relationships between these allergic diseases and reduced lung function, we hope to provide valuable scientific evidence for managing asthma patients who are co-morbid with multiple allergic conditions.</p><p><strong>Methods: </strong>In this study, we conducted Mendelian randomization (MR) analysis using data from the FinnGen database and the UK Biobank. We rigorously selected instrumental variables (IVs) based on established criteria and employed both univariable and multivariable MR approaches to investigate the relationship between various allergic diseases and significant declines in lung function.</p><p><strong>Results: </strong>In univariable MR analysis, the inverse variance-weighted (IVW) method or the weighted median approach indicated a causal relationship between allergic conjunctivitis, atopic dermatitis, and allergic asthma with significant declines in lung function. However, in multivariable MR analysis, the independent effects of atopic dermatitis and allergic conjunctivitis on lung function were no longer significant. Only allergic asthma continued to show a significant causal relationship with decreased lung function (OR [95%CI]: 1.019 [1.008-1.030], <i>p</i> < .001).</p><p><strong>Conclusions: </strong>This study suggests that while atopic dermatitis and allergic conjunctivitis may indirectly affect lung function and lead to significant declines, their independent effects are not notable when asthma is well-controlled. Therefore, clinicians should recognize that acute exacerbations of allergic diseases are unlikely to be the primary reason for significant declines in lung function among asthma patients with multiple allergic conditions, provided that their asthma is well-managed.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1296-1303"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism associated with severe dyspnea and asthma in 21,205 adults from the Danish population.","authors":"Kristin Felicia Nilausen, Delia-Ioana Radutiu, Eskild Morten Landt, Suzan Al-Shuweli, Børge G Nordestgaard, Uffe Bødtger, Morten Salling Olesen, Christina Ellervik, Morten Dahl","doi":"10.1080/02770903.2025.2478512","DOIUrl":"10.1080/02770903.2025.2478512","url":null,"abstract":"<p><strong>Background: </strong>Long-term consequences after a pulmonary embolism include lung function deficits, dyspnea, and chronic thromboembolic pulmonary hypertension. Recent studies suggest patients who experience pulmonary embolism may also be at increased risk of asthma.</p><p><strong>Methods: </strong>We tested the hypothesis that individuals with pulmonary embolism or deep vein thrombosis (venous thromboembolism) have lower lung function, or higher risks of dyspnea and asthma using data from 21,205 random adults from the Danish General Suburban Population Study.</p><p><strong>Results: </strong>Prevalences of pulmonary embolism, deep vein thrombosis, and venous thromboembolism were 0.60%, 1.7%, and 1.9%, respectively. Individuals with pulmonary embolism or deep vein thrombosis had FEV₁% predicted of 86% and 89% compared with 95% in individuals without venous thromboembolism (<i>t</i>-test: <i>p</i> < .001). Corresponding values for FVC% predicted were 92% and 94% versus 99% (<i>p</i> < .001). Individuals with versus without venous thromboembolism had adjusted odds ratios for light, moderate, and severe dyspnea of 1.6 (95% CI: 1.1-2.2), 1.8 (1.2-2.6), and 2.6 (1.8-3.8), respectively. Individuals with versus without venous thromboembolism had adjusted odds ratios for asthma and use of asthma medication of 1.6 (1.2-2.2) and 1.9 (1.4-2.6), respectively. The adjusted odds ratio for asthma in individuals with versus without venous thromboembolism was increased among individuals who received no treatment with anticoagulants (2.0, 1.4-3.0) compared to those who received treatment (1.0, 0.6-1.6) (<i>p</i> for interaction = .02).</p><p><strong>Conclusions: </strong>Individuals with venous thromboembolism have lower lung function, 2.6-fold higher risk of severe dyspnea, and 1.6-fold higher risk of asthma in the Danish population.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1364-1370"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sevoflurane-induction via the Flow-i ventilator in the pediatric intensive care unit for the treatment of status asthmaticus: a case report and literature review.","authors":"Ahmani DoDoo, Melissa Cregan, Kailey A Remien, Ambrish Patel","doi":"10.1080/02770903.2025.2482995","DOIUrl":"10.1080/02770903.2025.2482995","url":null,"abstract":"<p><strong>Introduction: </strong>Status asthmaticus is a severe asthma exacerbation commonly associated with hypercarbia, hypoxia, and respiratory acidosis that can be unresponsive to conventional therapies. Non-invasive positive pressure ventilation is utilized as the first modality of respiratory support. Inhaled anesthetic agents are non-standard treatment options which can be considered for their bronchodilator properties once the patient is intubated.</p><p><strong>Case report: </strong>We present a 14-year-old adolescent with a history of severe persistent asthma who was admitted to the pediatric intensive care unit (PICU) in status asthmaticus. The patient required intubation, was induced with sevoflurane, and mechanically ventilated with the Flow-i ventilator.</p><p><strong>Discussion: </strong>Status asthmaticus is described as severe asthma that is refractory to repeated administration of beta-agonists, while near-fatal asthma is described as exacerbations requiring intubation and mechanical ventilation. When mechanical ventilation and conventional therapies are inadequate, inhalational anesthetics and extracorporeal membrane oxygenation (ECMO) are considered. This article examines the use of sevoflurane as a treatment modality for pediatric patients with status asthmaticus highlighting the therapeutic approach and outcome.</p><p><strong>Conclusion: </strong>The use of inhaled anesthetic gases and advanced anesthesia machines can diversify and enhance treatment for patients with refractory status asthmaticus. With continuous monitoring of hemodynamics, anesthesia machines may be an integral therapeutic option for treating refractory status asthmaticus within the PICU without the need for extracorporeal life support.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1450-1457"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric screening tools in asthma and their barriers to clinical utilization: a systematic review.","authors":"Snigdha Widge, Jacquelyn Paquet, Ling Ling, Dilini Vethanayagam","doi":"10.1080/02770903.2025.2531499","DOIUrl":"10.1080/02770903.2025.2531499","url":null,"abstract":"<p><strong>Background: </strong>Chronic airway diseases such as asthma are often associated with psychiatric disorders like anxiety, depression, and posttraumatic stress disorder (PTSD), which occur 1.5-2.4 times more frequently in individuals with asthma. Despite this, these conditions are under-recognized. Various questionnaire-based screening tools exist for identifying these psychiatric conditions. This systematic review examines existing screening tools for asthma-related psychiatric conditions, evaluating their efficacy, effectiveness, and cost, with the goal of implementing them more broadly in clinical practice.</p><p><strong>Data sources: </strong>A search was performed using the databases MEDLINE, EMBASE, SCOPUS, CINAHL, and Web of Science for all relevant studies published before July 25, 2024. Costs for clinical use and copyright/open access status were assessed through internet searches and/or direct communication. Original validation studies of the screening tools were also reviewed.</p><p><strong>Study selection: </strong>A total of 23 studies were included for analysis. Eligible studies focused on screening anxiety disorders, depressive disorders and/or PTSD in individuals with asthma.</p><p><strong>Results: </strong>Eight psychiatric screening tools were identified, each validated and effective in screening for their respective anxiety disorders, depressive disorders, and PTSD. These tools effectively screen for psychiatric disorders, including in undiagnosed populations. Three are available at no cost for clinical use, while five require a fee.</p><p><strong>Conclusions: </strong>Considering multiple factors such as ease of administration, effectiveness, and cost, we recommend a combination of PHQ-9, GAD-7, and PCL-5 as screening tools for psychiatric comorbidity in primary care and specialty clinics managing adult asthma. Two of these tools are available in EMRs within Alberta.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled muscarinic antagonists during pregnancy in women with asthma: case series from a Dutch prospective observational cohort study.","authors":"N Kathiravetpillai, A R van Buul, M Ezinga, K Koehorst-Ter Huurne, S A Van Nederveen-Bendien","doi":"10.1080/02770903.2025.2531493","DOIUrl":"10.1080/02770903.2025.2531493","url":null,"abstract":"<p><strong>Introduction: </strong>A large proportion of women with asthma experience worsening of asthma during pregnancy. Well-controlled asthma during pregnancy decreases the risk of maternal and fetal complications. Long-acting muscarinic antagonists (LAMAs) are part of treatment guidelines for poorly controlled asthma. There are no clinical safety data available on LAMA and short-acting muscarinic antagonists (SAMAs) use in pregnancy.<b>Objective:</b> The aim was to evaluate asthma control and pregnancy outcomes in pregnant women with asthma using muscarinic antagonists.<b>Methods:</b> A prospective observational cohort of pregnant women with asthma referred to the asthma pregnancy outpatient clinic of the Haga Hospital, between 2018 and 2023, was obtained and retrospectively analyzed. Women using muscarinic antagonists were included. Outcomes were asthma control, asthma exacerbations and pregnancy outcomes.</p><p><strong>Results: </strong>Fourteen (8.9%) of 158 recruited pregnant women used muscarinic antagonists. Most women had poor asthma control with a mean (±SD) Asthma Control Questionnaire (ACQ) score of 2.4 (±1.3). Six (43%) women experienced an asthma exacerbation. One woman using LAMA throughout pregnancy had pre-eclampsia resulting in preterm birth, low birth weight and neonatal hospitalization. Another child was born with low birth weight and was small for gestational age. Two women developed maternal fever.<b>Conclusions:</b> A minority of women with asthma used muscarinic antagonists during pregnancy. Despite the use of muscarinic antagonists, asthma control remained poor during pregnancy. There were no major adverse pregnancy outcomes or congenital malformations in this case series. Since well-controlled asthma during pregnancy leads to fewer complications, pregnant woman with poorly controlled asthma on inhaled corticosteroid (ICS)/long-acting beta-2-agonist (LABA) should be encouraged to continue add-on asthma medication.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-7"},"PeriodicalIF":1.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of m6A methyltransferase <i>METTL3</i> on airway remodeling in bronchial asthma.","authors":"Lianqi Peng, Mi Li, Lijun Xiao, Liping Lei, Wenke Zhou, Yu Ye, Bo Xiao, Dong Yao, Biwen Mo","doi":"10.1080/02770903.2025.2531497","DOIUrl":"10.1080/02770903.2025.2531497","url":null,"abstract":"<p><strong>Background: </strong>Methyltransferase-like 3 (<i>METTL3</i>) is known to play a role in asthma airway remodeling and cell proliferation. Adenylate kinase 4 (AK4) regulates the proliferation of pulmonary artery smooth muscle cells and exerts its effects through the protein kinase B (AKT) pathway. However, the role of <i>METTL3</i> and AK4-AKT in bronchial smooth muscle cells remains unclear.</p><p><strong>Methods: </strong>Systemic <i>METTL3</i> knockout mice and a mouse model of asthma were established. Airway remodeling was assessed using pulmonary function tests, histopathological staining, and Western blot analysis. RNA sequencing (RNA-seq) was performed to detect changes in gene expression following <i>METTL3</i> knockdown. The 5-ethynyl-2'-deoxyuridine (EdU) assay was used to evaluate cell proliferation. Finally, the expression levels of relevant proteins were validated by Western blotting.</p><p><strong>Results: </strong>Compared with the control model group, the <i>METTL3</i> knockout group showed significantly reduced inflammatory cell infiltration, decreased collagen fiber deposition, and attenuated airway smooth muscle hyperplasia. RNA-seq revealed that the expression of numerous proliferation-related genes, including AK4, was upregulated following <i>METTL3</i> knockdown. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated that these genes were primarily enriched in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. The EdU assay demonstrated that <i>METTL3</i> knockdown inhibited cell proliferation. Western blot validation showed increased AK4 expression in lung tissues of the <i>METTL3</i> knockout group compared to the control group, while phosphorylated AKT (p-AKT) levels were reduced.</p><p><strong>Conclusions: </strong><i>METTL3</i> knockout inhibits airway smooth muscle hyperplasia and alleviates airway remodeling in asthma. This effect may be mediated through the regulation of AK4 and the AKT signaling pathway.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-14"},"PeriodicalIF":1.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuromodulation for the treatment of moderate to severe asthma - a pilot first-in-human clinical study.","authors":"Kurt Gehlsen, Angelica Carrasco, Jillian Hooghius, Stephen Pyles","doi":"10.1080/02770903.2025.2531501","DOIUrl":"10.1080/02770903.2025.2531501","url":null,"abstract":"<p><strong>Objective: </strong>This was a small, uncontrolled, first-in-human clinical study that evaluated the safety and efficacy of neuromodulation in patients with moderate to severe asthma.</p><p><strong>Methods: </strong>Patients diagnosed with chronic intractable pain and moderate or severe asthma on daily asthma medications were tested and subsequently implanted with a permanent spinal cord stimulator. Patients were followed for 12 months and monitored for changes in medication use, asthma control scores, quality of life, exacerbations, ER visits and hospitalizations.</p><p><strong>Results: </strong>11 patients were enrolled, 9 with asthma, and 2 with asthma plus COPD. 91% of patients achieved <i>a</i> > 50% reduction in all asthma medication usage. For all patients enrolled there was an 88% reduction in all asthma medication use and for patients with asthma alone, there was a 98% reduction in all medication use. 100% of enrolled patients reported an Asthma Control Test (ACT) >19 with improved breathing, no wheezing, no chest tightness, and no exacerbations (average increase of 13.3 points). 100% of the enrolled patients reported an improvement in quality of life with an average increase of 3.4 points using the Asthma Quality of Life Questionnaire (AQLQ). No ER visits or hospitalizations were reported due to asthma. There were no adverse events reported.</p><p><strong>Conclusions: </strong>Neuromodulation provided clinically meaningful improvements in asthma symptoms without the need for asthma medications and without adverse events.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-6"},"PeriodicalIF":1.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric chronic cough: Allergies, environmental factors, and asthma-associated inflammation.","authors":"Kaiwen Zheng, Qin Wang, Linyan Tang, Xing Chen","doi":"10.1080/02770903.2025.2537406","DOIUrl":"10.1080/02770903.2025.2537406","url":null,"abstract":"<p><strong>Background: </strong>Chronic cough (CC) is a common respiratory symptom in children, often linked to allergic conditions, environmental exposures, and potentially indicative of underlying asthma.</p><p><strong>Objective: </strong>To investigate the relationships of CC in children with allergic predispositions, environmental exposures, and airway inflammatory markers.</p><p><strong>Methods: </strong>A case-control study was conducted at a tertiary hospital. Data on cough duration, personal and family allergic histories, and environmental exposures were collected. Airway inflammation was assessed using fractional exhaled nitric oxide (FeNO₅₀), and lung function was evaluated <i>via</i> spirometry.</p><p><strong>Results: </strong>Children with CC showed a higher prevalence of allergic conditions, including rhinitis (74.77% vs. 24.13%, OR = 9.312, <i>p</i> < 0.0001), food allergy (59.81% vs. 27.59%, OR = 3.907, <i>p</i> = 0.0017), eczema (55.14% vs. 31.03%, OR = 2.731, <i>p</i> = 0.0213), and family history of allergies (71.96% vs. 27.59%, OR = 6.738, <i>p</i> < 0.001). Environmental exposures, such as household smoking (55.14% vs. 20.69%, OR = 4.712, <i>p</i> = 0.001) and mold exposure (28.68% vs. 7.35%, OR = 3.442, <i>p</i> = 0.0251), were more common in the CC group. CC children exhibited elevated FeNO₅₀ (median: 18 vs. 14 ppb, <i>p</i> = 0.0153) and impaired small airway function (FEF75%pred: 53.84 ± 20.21 vs. 65.07 ± 28.52, <i>p</i> = 0.0170).</p><p><strong>Conclusions: </strong>Pediatric CC is strongly associated with allergic predispositions, environmental exposures, and eosinophilic airway inflammation, potentially reflecting an asthma-related phenotype.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preserved ratio impaired spirometry and mortality in non-smoking asthma: a population-based cohort study.","authors":"Xiu Shi, Qingqing Li, Zhenhong Hu, Lijie Yang, Yunfan Wang, Hanxiang Nie","doi":"10.1080/02770903.2025.2526388","DOIUrl":"10.1080/02770903.2025.2526388","url":null,"abstract":"<p><strong>Background: </strong>Preserved ratio impaired spirometry (PRISm) is associated with asthma. However, it is unclear whether PRISm increases the risk of mortality in non-smoking asthma patients compared with normal spirometry.</p><p><strong>Methods: </strong>This prospective cohort study included 748 adult asthma participants with no smoking history and no airflow obstruction at baseline. Participants were divided into two groups: normal spirometry (FEV₁ ≥ 80% predicted) and PRISm (FEV₁ < 80% predicted). The median follow-up time was 9.6 years. Multivariable Cox regression analyses and Kaplan-Meier survival were used to assess the association between PRISm and all-cause mortality. All analyses took into account the complex survey design.</p><p><strong>Results: </strong>At baseline, 8.52% of participants exhibited PRISm. Multivariable Cox regression analysis showed that PRISm was independently associated with all-cause mortality after adjusting for confounding factors (adjusted hazard ratio = 6.57, 95% CI: 2.33-18.47, <i>p</i> < 0.001). Kaplan-Meier survival analysis showed that the survival rate in the PRISm group was significantly worse than that in the normal spirometry group (log-rank test <i>p</i> = 0.006). In a sensitivity analysis excluding participants with possible restrictive spirometry, this association remained with almost the same effect size (adjusted hazard ratio = 6.99, 95% CI: 1.67-29.29, <i>p</i> = 0.008).</p><p><strong>Conclusions: </strong>In asthma patients with no smoking history and no airflow obstruction at baseline, PRISm was significantly associated with an increased risk of all-cause mortality during follow-up. However, this result needs to be interpreted with caution due to the wide confidence intervals.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}